According to the New York Times (NYT) a week ago, a major new study found that lower doses of antipsychotics are better for the treatment of schizophrenia:
The findings, from by far the most rigorous trial to date conducted in the United States, concluded that schizophrenia patients who received smaller doses of antipsychotic medication and a bigger emphasis on one-on-one talk therapy and family support made greater strides in recovery over the first two years of treatment than patients who got the usual drug-focused care.
The paper, by John M. Kane and colleagues and published in the American Journal of Psychiatry (AJP), is called Comprehensive Versus Usual Community Care for First-Episode Psychosis and it presents the results of the NIMH "RAISE" study. It's an impressive paper. However, it's not a paper about dose reduction. So the NYT's coverage was misleading. The word "dose" (including variants such as "dosage") appears just ...
